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Fabry disease (FD) is an underdiagnosed pathology due to its
symptomatology that overlaps with various systemic and rheumatic
disorders, including familial Mediterranean fever (FMF). We examined the
Mediterranean fever (MEFV) and α-galactosidase A (GLA) genes, whose
mutations are responsible for FMF and FD, respectively, in 42 unrelated
patients diagnosed with FMF, which revealed significant ambiguity
regarding some of the symptoms which are also present in FD. The
objective of this study was to determine the spectrum of mutations present
in these genes, in order to identify cases of mistaken diagnosis of FMF
and/or missed diagnosis of FD. Ten out of 42 patients had one mutation in
homozygosis or two different mutations in heterozygosis in the MEFV
gene; 20/42 had a single heterozygous mutation, and 12/42 did not have
genetic alterations in MEFV. The analysis of the GLA gene conducted on
all the samples revealed that three subjects, and some members of their
families, had two different exonic mutations associated with FD. Family
studies allowed us to identify eight other cases of FD, bringing the total
undiagnosed subjects to 11/53. Analyzing the MEFV and GLA genes in
patients with clinical diagnoses of FMF proved to be fundamentally
important for the reduction of diagnostic errors.
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Fabry disease (FD) is a lysosomal enzymopathy, caused
by the mutations in the α-galactosidase A (GLA) gene,
with extremely heterogeneous clinical manifestations
(1). As FD is an X-linked disease, affected women
are mostly heterozygotes with random X-chromosome
inactivation, and they generally have less-evident
symptoms, making diagnosis more difficult (2).
FD is considered a rare pathology, having an esti-
mated incidence for its classical form of 1:40,000 live
male births. However FD is still underdiagnosed, the
average delay from the onset of symptoms to diagno-
sis is more than a decade (3). The underestimation of
the disease is mainly because of its clinical expression,
as FD can be confused with other systemic disorders
which present similar symptoms and is often treated as
an organ pathology.
Literature reports cases in which the overlapping of
clinical indicators of FD with certain rheumatic disor-
ders, such as familial Mediterranean fever (FMF), made
the diagnosis of FD difficult and time consuming (4, 5).
Both diseases are hereditary disorders with similarities
in their onset of symptoms and clinical manifestations:
the first problems arise during childhood, with clini-
cal features such as recurrent febrile episodes, abdom-
inal and joint pain, gastrointestinal disorders and renal
damage.
FMF is considered a genetic autosomal recessive
disease occurring in Mediterranean and Middle Eastern
populations (6). The onset of the disease is charac-
terized by recurrent acute febrile episodes of brief
duration, associated with painful manifestations. The
standard treatment for FMF is daily administration
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of colchicine, which aids in the control of symptoms
and prevents the occurrence of renal amyloidosis.
Mediterranean fever (MEFV ) is the gene responsible
for the disease and the genetic diagnosis of FMF
is positive when one mutation in homozygosis or
two different mutations in heterozygosis (combined
heterozygotes) are present in the MEFV gene (7).
However, it has been observed that up to 30% of
patients with FMF-compatible symptomatology and
optimal response to colchicine had only one mutation
in the MEFV gene (8).
In order to identify possible cases of mistaken
diagnosis of FMF and/or missed diagnosis of FD, we
analyzed mutations in the MEFV and GLA genes of
42 unrelated patients with clinical diagnoses of FMF,
which revealed significant ambiguity regarding some of
the symptoms which are also present in FD.
Materials and methods
Patient specimens
We studied 42 patients, along with family members of
some of these patients, from Southern Italy, the part of
the country with the highest frequency of FMF. Signed
informed consent was obtained from all participants for
genetic analysis and publication of data.
Peripheral blood was collected, using ethylenedi-
aminetetraacetic acid as an anticoagulant. DNA samples
were isolated from whole blood by column extraction.
HRM analysis and DNA sequencing
A pre-sequencing screening was performed on DNA
samples by high resolution melting (HRM) analysis
for the study of the exons of the MEFV and GLA
genes. The Light Cycler 480 system (Roche Applied
Science, Penzberg, Germany) was used, as previously
described (9).
Purified polymerase chain reaction products were
sequenced using the automated DNA sequencer at BMR
Genomics.
α-Galactosidase activity assay
The activity of GLA was determined by the ‘dried blood
filter paper’ test described by Chamoles et al., with
minor modifications (10).
Results
We performed the genetic study of the MEFV and
GLA genes by HRM analysis, and sequencing of DNA
extracted from blood samples of 42 patients with
clinical diagnoses of FMF. The results of the genetic
analysis and clinical data are reported in Table 1.
In the cases that we studied, we found several
mutations in the MEFV gene that have been previously
described in the literature (http://fmf.igh.cnrs.fr): 7/42
subjects (16.7%) had a homozygous mutation; 3/42
subjects (7.1%) were combined heterozygotes; in 20/42
subjects (47.6%) a single mutation in the MEFV gene
was found. Twelve of 42 subjects (28.6%) did not have
any mutations in MEFV.
We also conducted analysis of the GLA gene on
all the samples, and for the patients found to have
mutations in the gene, the analysis was extended to
their relatives. Two different mutations were found in
three unrelated subjects, as well as in some members
of their families. Two patients (23 and 38) were found
to have the S126G mutation, also known as c.376A>G
(Fig. 1a–c), on exon 3, which is responsible for the
classical form of FD (11), another (patient 27) was
found to have the M51I mutation, also known as
c.153G>A (Fig. 1d–f), on exon 1, which according
to literature is responsible for a late-onset form
of FD (12).
Patient 23 is a 20-year-old female affected by acute
bilateral arthritis of the phalanges, and fevers ≤38◦C
which is not related to other pathologies. The fever
lasted for several months as night fever and did not
respond to paracetamol, cortisone and/or antibiotics and
was accompanied by persistent arthralgia. In her med-
ical history, the patient also reported mild acropares-
thesias and other paroxysmal pains, in addition to renal
symptoms and mild left ventricular hypertrophy. The
genetic analysis of MEFV gene in the patient reported
one mutation in heterozygosis, P369S (Table 2A). The
same genetic alteration was found in the patient’s father,
who had also the mutation E148Q, making him a com-
bined heterozygote. The patient’s sister had the muta-
tion E148Q in heterozygosis whereas her mother did
not have any mutations in MEFV . The analysis of the
GLA gene in patient 23 revealed the S126G mutation
on exon 3 (Table 2A); her mother and sister also turned
out to be carriers of the same mutation. They presented
many systemic symptoms whose mild nature is a char-
acteristic of female subjects affected by FD, due to the
phenomenon of random X-chromosome inactivation.
Analysis of GLA activity in members of this family
showed that the female carriers of the S126G mutation
had residual enzymatic activity slightly lower than the
norm (Table 2A).
Patient 27 is an 18-year-old female with recurrent
bouts of abdominal and distal extremity pain, accom-
panied by fever for approximately 6 months. During
these episodes, she was treated with non-steroidal anti-
inflammatory drugs, antibiotics and antipyretics, with-
out any effect on the fever. The patient also presented
mild cardiac and neurological symptoms. The inter-
mittent nature of the clinical manifestations and the
presence of fever during the painful attacks have led
her physician to consider FMF as the presumptive
diagnosis. The presence of proteinuria, which may be
attributable to the development of amyloidosis, was
also taken to be evidence of FMF. The analysis of
her MEFV gene reported one mutation in heterozy-
gosis, A744S, which is also present in her father
(Table 2B). The analysis of the GLA gene in the patient
revealed the M51I mutation on exon 1 (Table 2B).
The same genetic alteration was also found in the
patient’s mother, aunt (her mother’s sister), uncle (her
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Table 1. Genetic diagram of GLA and MEFV and clinical data of patients with presumptive diagnosis of FMF
No Sex/age MEFV mutations
GLA
mutations
Fever
attacks
Abdominal
pains Arthritis
Gastrointestinal
manifestations
Recurrent
headaches Other signs
Family
study
1 M/21 M694V/M694V − + + + + + – ND
2 F/24 M694V/M694V − + + + + + – ND
3 M/20 M694V/M694V − + + − + − – ND
4 M/8 M694V/M694V − + − + − + – ND
5 M/20 M680I/M680I − + + − + − – ND
6 M/47 M680I/M680I − + + − + − – ND
7 M/26 R761H/R761H − + + − + − – ND
8 F/56 M694V/E148Q − + + + + + Angiokeratomas,
renal, neurologic
ND
9 M/37 M694V/ M694I − + + + + − Cardiac ND
10 M/38 M680I/V726A − + + − − + – ND
11 F/36 M680I − + + + + + Angiokeratomas,
cardiac
ND
12 F/37 M680I − − − + − + – ND
13 M/25 M680I − − − + − + – ND
14 M/57 M680I − − − − − + – ND
15 F/21 M680I − − − − − − Renal ND
16 F/41 E148Q − + − + + + Cardiac, neurologic ND
17 M/18 E148Q − + + + + + – ND
18 F/61 E148Q − − − + − + Angiokeratomas ND
19 M/8 E148Q − − + + − + – ND
20 M/10 E148Q − + + − − + – ND
21 F/7 E148Q − + − − − − – ND
22 M/3 P369S − + + − − − – ND
23 F/20 P369S S126G + − + − − Cardiac, renal +
24 M/7 − − + + + − − – ND
25 F/42 − − + + − + + – ND
26 F/40 − − + + + − − Angiokeratomas,
cardiac,
neurologic
ND
27 F/18 A744S M51I + + + − − Cardiac,
neurologic, renal
+
28 F/30 − − + + − + − – ND
29 F/8 − − + − + − + Neurologic ND
30 M/17 − − − − + − + – ND
31 M/11 − − + + + − − – ND
32 M/53 M694V − − − + − + – ND
33 F/57 M694V − − − + − − Cardiac ND
34 M/23 M694V − + + − + + – ND
35 M/6 K695R − + + − − − – ND
36 F/18 R761H − + + + + + Renal ND
37 F/33 V726A − + − + + + Renal, cardiac ND
38 F/30 − S126G + + − + − – +
39 F/35 − − + − − + + – ND
40 F/45 − − + − + + + Cardiac, neurologic ND
41 F/64 − − + + + + + Cardiac, neurologic ND
42 F/20 − − + − − + + – ND
+, yes; −, no; F, female; FMF, familial Mediterranean fever; GLA, α-galactosidase A; M, male; MEFV, Mediterranean fever; ND, not
determined.
mother’s brother) and cousin (son of the aunt). The
patient’s mother suffered from left ventricular hypertro-
phy, recurrent headaches and intolerance to heat and/or
cold; a careful medical history revealed in the other
family members carrying the same mutation several
systemic symptoms with renal, cardiac and neurological
manifestations. The GLA activity in patient 27, her
mother and aunt were slightly below the norm, while
that of the uncle and cousin were completely absent
(Table 2B).
Patient 38 is a 30-year-old woman who pre-
sented with recurrent fever and significant gastroin-
testinal involvement with repeated attacks of abdom-
inal pain. The inflammatory background, together with
her medical history, suggested a diagnosis of FMF. The
genetic analysis of MEFV in the patient did not report
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Fig. 1. (a) High resolution melting (HRM) analysis of exon 3 of the α-galactosidase A (GLA) gene in patients 23 and 38 (curves indicated by
dashed arrow) and in healthy control (curve indicated by solid arrow). (b) Portion of the electropherogram of exon 3 of the GLA gene in patient
23, showing c.376A>G mutation in heterozygosis (corresponding to S126G) indicated by the arrow. (c) Portion of the sequence of exon 3 of the
GLA gene in patient 23 aligned with the corresponding sequence of a wt control. (d) HRM analysis of exon 1 of the GLA gene in patient 27 and
her mother (curves indicated by dashed arrow) and in a wt control (curve indicated by solid arrow). (e) Portion of the electropherogram of exon
1 of the GLA gene in patient 27, in which c.153G>A mutation in heterozygosis (corresponding to M51I) is indicated by the arrow. (f) Portion of
the sequence of exon 1 of the GLA gene in patient 27 aligned with the corresponding sequence of a wt control. The mutations A>G and G>A are
indicated by the letter R [International Union of Pure and Applied Chemistry (IUPAC) nomenclature].
any mutations; the analysis of GLA however, revealed
the S126G mutation on the exon 3 (Table 2C). Her
mother and sister also had the same mutation. Clini-
cal analyses in these two subjects showed mild sys-
temic symptoms, such as recurrent headaches, abdom-
inal pains and cardiac involvement with signs of left
ventricular hypertrophy. The residual enzymatic activ-
ity of GLA in the patient 38 and her relatives carrying
this mutation (Table 2C) is explained by the fact that
they are all female.
Discussion
FD is a genetic disease that is currently underdiagnosed
because of its clinical manifestations that can suggest
other pathologies. In fact, some features of FD, in
the absence of a severe clinical picture, can easily be
confused with those of other systemic disorders leading
to its misdiagnoses.
In cases in which the patient presents recurrent
attacks of fever, abdominal and joint pains, gastroin-
testinal problems and renal damage, in the absence of
other findings indicative of a specific systemic disorder
and in the presence of a specific ethnic background,
clinicians are often led to diagnose FMF. Although
it is a rare disease it becomes the primary diagnostic
hypothesis.
In this article, we present the results of a study
conducted on 42 patients whose clinical manifestations
and geographic origins led to clinical diagnoses of FMF.
For these subjects, we have determined the spectrum
of mutations present in the MEFV and GLA genes
to identify cases of possibly mistaken FMF diagnoses
and/or missed diagnoses of FD.
Our results have shown that in 23.8% of the subjects
studied who had two mutations in the MEFV gene,
the symptomatology was strongly attributable to FMF.
Another 47.6% of the studied subjects had a single
mutation in heterozygosis in the MEFV gene; a detailed
clinical analysis of these patients revealed that they
showed a mild FMF phenotype, and some of them also
had other signs and symptoms not related to the disease
(Table 1). Several hypotheses have been proposed
to explain the development of clinical symptoms
in subjects carrying a single mutation in a disease
such as FMF, which is considered to be recessive.
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Table 2. GLA and MEFV genetic diagram of the 3 families studied
Kinship Sex/age Enzyme activity (nmol/ml/h) GLA mutation MEFV mutation
A Family 1 Patient 23 F/20 3.2 S126G P369S
Father M/54 5.6 − E148Q/P369S
Mother F/53 2.3 S126G −
Sister F/23 3.2 S126G E148Q
B Family 2 Patient 27 F/18 2.6 M51I A744S
Father M/49 5.3 − A744S
Mother F/52 3.5 M51I −
Uncle M/54 0.0 M51I −
Aunt F/51 3.3 M51I −
Cousin M/24 0.0 M51I −
C Family 3 Patient 38 F/30 3.9 S126G −
Father M/61 5.5 − −
Mother F/57 2.6 S126G −
Sister F/33 3.3 S126G −
−, no mutation; F, female; GLA, α-galactosidase A; M, male; MEFV, Mediterranean fever.
Normal values of GLA activity assayed in whole blood are >3.5 nmol/ml/h; however, in females, this assay give no clear indication,
as is discussed in the text.
These include the pseudo-dominant inheritance of
some mutations and the possible involvement of other
genes (modifier genes) that contribute to the clinical
variability of heterozygous patients. Furthermore, due
to the overlapping of clinical features of FMF with
other disorders characterized by systemic involvement,
the symptomatology may be determined by another
disease caused by mutations in other genes. In our
study, 28.6% of the patients studied did not have genetic
alterations in MEFV, so in these subjects, the presence
of symptoms may be due to other diseases with similar
clinical manifestations (4).
The results of the study of the GLA gene in subjects
harboring a single genetic alteration in MEFV, or
without mutations in this gene, were quite interesting;
indeed, in 9.4% of the cases, the S126G and M51I
exonic mutations were found which, according to
literature, are responsible for FD. This percentage is
very significant, and confirms that the presence of the
disease is underestimated. The S126G and M51I amino
acid substitutions present in three unrelated subjects
of the study were also detected in other members
of their families who, upon careful analysis, showed
some symptoms of FD. In fact, the diagnoses of FD
suggested the need to conduct a family study, which
allowed the disease to be identified in another eight
members of their families, bringing the total number
of undiagnosed subjects to 11/53.
The clinical symptoms presented by subjects carrying
mutations in the GLA gene can thus be explained by the
diagnosis of FD, which was not considered at the begin-
ning. The correct diagnosis of FD is important not only
for etiological reasons but, above all, for the initiation
of the correct therapy so that the patients do not undergo
useless doses of colchicine because of the diagnosis of
FMF. Instead, they can undergo enzyme replacement
therapy which is available for the treatment of FD. Fur-
thermore, the diagnosis of FD, as it suggests the need
for the analysis of other family members, can facilitate
the identification of the disease in other relatives who
may be asymptomatic because of their age or sex.
In conclusion, we are convinced that the analysis
of the MEFV and GLA genes, as well as a careful
analysis of family medical history and other diagnostic
tools which can help identify the clinical features of
FD, should be performed for all patients presenting
ambiguous symptomatological patterns of FMF.
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